In this study, prompted by the observation of the CXCL13 overexpression on certain NSCLC patients, we implemented the strategy to co-express CXCR5 with the anti-EGFR-CAR-T to facilitate T cell migration to the tumor site. Here, CXCR5 is linked to neoplasm.